Monte Rosa Therapeutics, Inc.

US$10.57As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GLUEHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (13.29%)
Div yield —
ROE (35.30%)
Biotechnology
Beta (5Y) 1.38
PE TTM —
TSR TTM (17.74%)
Mkt cap US$903.2M
ROIC (23.03%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$13
20.51%
61.86%
Hold 6|0|5|7|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.10
0.11
0.11
0.12
1.88%
7.17%
16.01%
25.80%
Revenue$M
91.81
90.71
89.60
88.45
3.31%
(1.79%)
(3.32%)
(4.76%)
Peers (US$903.2M)
Cap (US$)
PE
902.0M
—
Capital
TTM
5Y
10Y
Leveragex
0.373
(0.512)
(0.496)
EBIT/Intx
10.95
0.236
0.223
Own earn%
(27.48)
82.92
63.84
Sh yield%
21.08
17.36
17.40
Owners
Insiders/Inst%
8.52
36.44
Short interest%
2.10
SBC / revenue%
1.66
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
15–22
$1 testx
—
Incr. ROIC%
2